The acquisition of Mirus Bio by MilliporeSigma for $600 million is set to bring together two decades of experience in nucleic acid delivery with a broad portfolio, scale, and global reach. Mirus Bio, based in Madison, is a manufacturer of transfection regents used in gene therapies. This acquisition will combine their expertise with MilliporeSigma’s comprehensive portfolio and life sciences business, Merck KGaA.
MilliporeSigma’s Process Solutions business provides solutions for viral vector manufacturing to advance cell and gene therapies from preclinical through commercial production. Their portfolio includes cell lines, cell culture media, processing chemicals, buffers, enzymes, systems, filters, hardware, and consumables to support the entire viral vector manufacturing process. Additionally, their Life Science Services business offers contract testing and development services for viral vector manufacturing.
Matthias Heinzel, CEO of the Life Science business at Merck KGaA emphasized the potential of viral vector-based cell and gene therapies with over 20 approvals in the last 10 years and projected growth of 30% until 2028. This acquisition will enable MilliporeSigma to meet the increasing demand for these life-saving therapies.
The acquisition is expected to be completed in the third quarter of this year.
